Despite extensive efforts, EGFR-targeted therapies (e.g., tyrosine kinase inhibitors, monoclonal antibodies, and vaccine-based approaches like rindopepimut) have shown limited efficacy in clinical trials, largely due to challenges in BBB penetration and intrinsic tumor resistance (29). Here, EGFR is linked to neoplasm.